AUA 2024: Dr. Weiner previews key prostate cancer research

Feature
Video

Adam B. Weiner, MD, highlights several studies in prostate cancer set to be presented at the upcoming 2024 American Urological Association Annual Meeting.

In this video, Adam B. Weiner, MD, highlights 5 studies in prostate cancer that will be presented at the upcoming 2024 American Urological Association (AUA) Annual Meeting, which will take place on May 3 – 6 in San Antonio, Texas. Weiner is a current urologic oncology fellow at the University of California, Los Angeles.

During the discussion, Weiner highlights the following presentations:

  • P2s: Efficacy of [177Lu]Lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore)
  • P2s: Apalutamide and androgen deprivation therapy for the treatment of high-risk localized prostate cancer following radical prostatectomy in Apa-RP: a multicenter, open-label, single-arm ph
  • PD01-03: Third interim analysis (IA3) of the DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
  • PD01-06: Prostate-specific antigen dynamics from the phase 3 EMBARK trial: A post hoc analysis
  • PD39-06: A randomized clinical trial comparing focal ablation and radical prostatectomy in patients with unilateral clinically significant prostate cancer. Intention to treat analysis at two-year follow-up
Related Videos
Kevin M. Wymer, MD
Karine Tawagi, MD
Dr. Jasmeet Kaur in an interview with Urology Times
Dr. Martin Voss in an interview with Urology Times
Dr. Jacqueline Brown in an interview with Urology Times
blurred clinic hallway
Dr. Dalia Kaakour in an interview with red Urology Times backdrop
Dr. Maria Teresa Bourlon in an interview with Urology Times
Related Content
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma

Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma

February 2nd 2024
Article

“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.

blurred photo of a clinic hallway

2023 AUA highlights in benign urology

May 28th 2023
Podcast

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

Human kidney cross section | Image Credit: © hywards - stock.adobe.com

Investigators report on real-world recurrence, survival rates in RCC

January 31st 2024
Article

“Our study provides real-world recurrence and survival rates, [however], a major limitation is the retrospective nature of the analysis,” wrote the investigators, led by Viktor Gruenwald, MD, PhD.

Speaking of Urology: 2023 AUA Highlights

Speaking of Urology: 2023 AUA Highlights

May 12th 2023
Podcast

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

APL-1202 plus tislelizumab combo shows promise in MIBC

APL-1202 plus tislelizumab combo shows promise in MIBC

January 29th 2024
Article

Overall, the pathological complete response rate among patients who received APL-1202 plus tislelizumab was 39%, compared with 21% among those who received tislelizumab alone.

3d rendered medically accurate illustration of kidney cancer | Image Credit: © SciePro - stock.adobe.com

First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC

January 29th 2024
Article

“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.

© 2024 MJH Life Sciences

All rights reserved.